| Literature DB >> 31322836 |
Jin Lu1, Zhong Ren2, Xun Liu3, You-Jia Xu4, Qiang Liu5.
Abstract
OBJECTIVES: To investigate the knowledge and practices of Chinese doctors in the management of osteoporotic fractures after the Chinese osteoporotic fracture guidelines update and aseries of medical education in 2017.Entities:
Keywords: Chinese osteoporotic fracture guidelines; Medical education; Osteoporotic fracture; Questionnaire survey
Mesh:
Substances:
Year: 2019 PMID: 31322836 PMCID: PMC6712375 DOI: 10.1111/os.12476
Source DB: PubMed Journal: Orthop Surg ISSN: 1757-7853 Impact factor: 2.071
Survey questionnaire
| Question category | Question number | Question content | Question options |
|---|---|---|---|
| Osteoporosis diagnosis | Q1 | Do you agree that osteoporosis can be diagnosed clinically by the occurrence of fragility fractures? | A. AgreeB. DisagreeC. Not sure |
| Q2 | The bone mineral density criterion for osteoporosis diagnosis is: | A. T ≥ −1.0 SD B. ‐2.5 SD < T < ‐1.0 SD C. T ≤ −2.5 SD | |
| Q4 | The specific bone turnover biochemical markers recommended by the IOF are: | A. P1NP, S⁃CTXB. Bone alkaline phosphatase, osteocalcinC. Vitamin D, calcium phosphateD. Thyroid hormone, parathyroid hormone | |
| Characteristics and treatment principles of osteoporotic fractures | Q3 | Which descriptions of the characteristics of osteoporotic fracture are correct in your opinion? (Choose one or more) | A. Rapid bone loss will occur when a patient stays in bed after fracture, and will aggravate osteoporosis;B. Abnormal bone reconstruction, slow healing process, long recovery time, delayed fracture healing or even non‐healing;C. Significantly increased risk of re‐fracture at the same site or other sites;D. Low bone mass in the fracture site, poor bone quality, and most are comminuted fractures, which is difficult to achieve reduction;E. Poor stability of internal fixation treatment; internal fixation and implants are easy to loosen and escape, and the bone graft is easily absorbed;F. More common in the elderly who are with poor general condition and with other organ diseases or systemic diseases. Complications may occur during treatment and increase the complexity of treatment. |
| Q5 | The basic principles of treatment of osteoporotic fractures are: (Choose one or more) | A. Reduction B. Fixation C. Functional exercise D. Anti‐osteoporosis treatment | |
| Q6 | The common sites of osteoporotic fracture are: (Choose one or more) | A. Spine B. Hip C. Distal radius D. Proximal humerus | |
| Drug treatment | Q7 | The dosages of calcium and vitamin D you usually give to patients in the early stage after osteoporotic fracture are: | A. Ca 400 mg/day, VitD 200 IU/dB. Ca 600 mg/day, VitD 400 IU/dC. Ca 1000 mg/day, VitD 800 IU/dD. Ca 1200 mg/day, VitD 800 IU/dE. Ca >1200 mg/day, VitD 1200 IU/d |
| Q8 | Which type of anti‐osteoporosis drug is the most prescribed in your clinical practice? (Choose one) | A. Bisphosphonates B. Selective estrogen receptor modulators, estrogens C. Calcitonin D. Anabolic agents E. Active vitamin D F. Chinese patent medicine | |
| Q9 | For patients who have used anti‐osteoporosis drug, should the anti‐osteoporosis drug be discontinued after osteoporotic fracture? | A. Yes B. Reassessing osteoporosis instead of blindly discontinuing the drug C. Unclear | |
| Q10 | Which is the optimal treatment for osteoporotic fracture patients who did not use anti‐osteoporosis drugs before osteoporotic fracture? | A. Use anti‐osteoporosis agents as soon as fracture treatment completed when the patient's general condition is stableB. Start anti‐osteoporosis medication after fracture healingC. Only basic supplement therapy with calcium and vitamin D D. Only use short‐term calcitonin to suppress acute pain | |
| Drug selection | Q11 | Do you agree that standardized use of bisphosphonates after osteoporotic fractures would not adversely affect fracture healing? | A. Agree B. Disagree C. Not sure |
| Q12 | Under what circumstances will you choose anabolic drugs to treat osteoporotic fractures? | A. For patients with osteoporotic fracture treated with anti‐bone resorption drugs for many yearsB. For postmenopausal women who have osteoporotic vertebral fractures or hip fractures for many timesC. For patients with multiple osteoporotic fracturesD. Not to be used | |
| Medication time | Q13 | Which of the following statements do you agree about the effects of bisphosphonates on fracture healing and internal plants? (Choose one or more) | A. Use of bisphosphonates after osteoporotic fracture may lead to increased osteophytes, increased mineralization, and no delayed fracture healing.B. Use of bisphosphonates after internal fixation can inhibit further loss of bone mass, improve stability of internal fixation, and reduce incidence of internal fixation displacement.C. Use of bisphosphonates after artificial joint replacement for osteoporotic hip fracture can increase hip bone mass, reduce bone loss around the prosthesis, and reduce incidence of prosthesis loosening. |
| Duration of treatment | Q14 | Which do you think is the reasonable duration of bisphosphonates treatment for patients with osteoporosis? | A. <3 monthsB. 3–12 months (including 12 months)C. 1–3 years (including 3 years)D. 3–5 yearsE. Not sure |
| Patient management | Q15 | For osteoporosis patients after fracture healing, which department do you usually advise them to visit to continue anti‐osteoporosis treatment? | A. OrthopaedicsB. EndocrinologyC. RehabilitationD. GeriatricsE. OsteoporosisF. RheumatologyG. Chinese Medicine |
| Q16 | What is the revisit and follow‐up rate in patients with osteoporotic fracture in your clinical practice? | A. <30% B. 30%–50% C. >50% | |
| Q17 | Does your hospital have any system, personnel or program for long‐term management of osteoporotic fractures? | A. Yes B. No C. Under arrangement | |
| Feedback of respondents | Q18 | Are you satisfied with the content and discussion of this meeting? Please provide your valuable comments and suggestions. | A. Satisfied B. Fair C. Unsatisfied |
| Q19 | What is your expertise? | A. SpineB. JointC. TraumaD. General orthopaedics and othersE. EndocrineF. RheumatismH. GeriatricsI. OsteoporosisJ. General internal medicine and others | |
| Q20 | What is your job title? | A. Chief physician B. Deputy chief physician C. Attending physician D. Resident physician | |
| Q21 | What is the grade of your hospital? | A. Tertiary hospital B. Secondary hospital C. Primary hospital | |
| Q23 | How many times have you attended osteoporosis‐related training or meetings in the past year? | A. <3 timesB. 3–7 timesC. >7 times |
Characteristics of respondents
| Variable | Category | Number of respondents | % |
|---|---|---|---|
| Grade of the hospital working in | Tertiary hospital | 260 | 83% |
| Secondary hospital | 53 | 17% | |
| Primary hospital | 1 | 0% | |
| Job title | Chief physician | 63 | 20% |
| Deputy chief physician | 92 | 29% | |
| Attending physician | 110 | 35% | |
| Resident physician | 49 | 16% | |
| Specialty | Spine | 101 | 32% |
| Joint | 35 | 11% | |
| Trauma | 36 | 12% | |
| General orthopaedics and others | 10 | 3% | |
| Endocrine | 59 | 19% | |
| Rheumatism | 44 | 14% | |
| Geriatrics | 15 | 5% | |
| Osteoporosis | 13 | 4% | |
| General internal medicine and others | 1 | 0% | |
| Frequency of attending medical education | <3 times | 161 | 51% |
| 3–7 times | 122 | 39% | |
| >7 times | 30 | 10% |
Total 313 valid responses.
Figure 1Responses to Q1 (Do you agree that osteoporosis can be diagnosed clinically by the occurrence of fragility fractures?). (A) Overall analysis; (B) analysis by frequency of medical education; (C) analysis by job title.
Figure 2The most prescribed daily dosages of calcium and vitamin D.
Figure 3The most prescribed anti‐osteoporosis drugs.
Figure 4The knowledge on timing of anti‐osteoporosis medication.
Figure 5Recommended duration of bisphosphonates treatment. (A) Overall analysis; (B) analysis by frequency of attending medical education; and (C) analysis by job title.
Figure 6Follow‐up rate of patients with osteoporotic fracture. Group A: doctors from hospitals with long‐term management program; Group B: doctors from hospitals without long‐term management program; Group C: doctors from hospitals with long‐term management programs at planning or preparatory stage.
Figure 7Responses to Q11 (Do you agree that standardized use of bisphosphonates after osteoporotic fractures would not adversely affect fracture healing?), comparing with the data published in 2016.
Figure 8The knowledge on duration of bisphosphonates treatment, comparing with the data published in 2016.